Trial Results Presentations, Public Offerings, Acquisitions and Extension Study Results - Research Report on Medtronic, Steris,

  Trial Results Presentations, Public Offerings, Acquisitions and Extension
 Study Results - Research Report on Medtronic, Steris, Intercept, Wright, and
                                   Synageva

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Medtronic,
Inc. (NYSE: MDT), Steris Corp. (NYSE: STE), Intercept Pharmaceuticals, Inc.
(NASDAQ: ICPT), Wright Medical Group Inc. (NASDAQ: WMGI), and Synageva
BioPharma Corp. (NASDAQ: GEVA). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Medtronic, Inc. Research Report

On October 17, 2013, Medtronic Inc. (Medtronic) announced that it will present
its CoreValve U.S. Pivotal Trial results at the 25th Annual Transcatheter
Cardiovascular Therapeutics (TCT) Symposium in San Francisco on October 29,
2013. "Unveiling the CoreValve U.S. Pivotal Trial data for the first time is a
significant milestone as we work toward bringing more therapy options to
patients in the U.S.," said John Liddicoat, M.D., Senior Vice President,
Medtronic, and President of the Medtronic Structural Heart Business at
Medtronic. "This study will provide vital information for physicians and their
U.S. patients, many of whom have had no good option for treating their aortic
stenosis." The Full Research Report on Medtronic, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/bc94_MDT]

Steris Corp. Research Report

On October 15, 2013, Steris Corp. (Steris) announced the schedule of its
earnings release and the Company will report its Q2 FY 2014 financial results
before market opens on October 30, 2013. Following the release, the Company
will host a conference call at 10:00 a.m. ET. The call can be accessed live
over the Internet through the Company's website. The Full Research Report on
Steris Corp. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/8e31_STE]

Intercept Pharmaceuticals, Inc. Research Report

On October 8, 2013, Intercept Pharmaceuticals, Inc. (Intercept) announced the
pricing of an underwritten public offering of 1.5 million shares of its common
stock by certain selling stockholders at a public offering price of $62.50 per
share. Further, the selling stockholders have granted the underwriters a
30-day option to purchase up to an additional 225,000 shares of common stock.
Intercept further reported that it will not receive any proceeds from the sale
of the shares of common stock by the selling stockholders in the offering. The
Full Research Report on Intercept Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b477_ICPT]

Wright Medical Group Inc. Research Report

On October 16, 2013, Wright Medical Group, Inc. (Wright Medical) announced
that it has entered into a definitive agreement to acquire Biotech
International. The acquisition will significantly expand Wright's direct sales
channel in France and international distribution network, with the addition of
Biotech's complementary extremity product portfolio. Robert Palmisano,
President and CEO of Wright, commented, "The acquisition of Biotech
International is an excellent fit for our Extremities business, enabling us to
immediately expand our direct foot and ankle presence in Europe and add a base
of extremity revenue that we can effectively grow on a go-forward basis." The
transaction is expected to close in the Q4 of 2013. The Full Research Report
on Wright Medical Group Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/1782_WMGI]

Synageva BioPharma Corp. Research Report

On October 11, 2013, Synageva BioPharma Corp. (Synageva) announced 78-week
results from an ongoing extension study with sebelipase alfa in adults with
Lysosomal Acid Lipase (LAL) Deficiency. The Company informed that the results
were presented during an oral presentation at the North American Society for
Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting
held in Chicago, Illinois. Synageva reported that six of the eight patients
enrolled in the Phase 1/2 extension study completing 18 months of treatment
showed sustained improvements in biochemical markers of liver damage and in
the dyslipidemia associated with LAL Deficiency. The Full Research Report on
Synageva BioPharma Corp. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/8624_GEVA]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.